2030 Labelling Pharmaceutical Companies 
Express Pharma
SEPTEMBER 18, 2024
Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.
Express Pharma
MAY 13, 2024
With other pharmaceutical companies entering the race for developing the first marketed therapy against bronchiectasis, the great opportunity in the market is underlined, says GlobalData , a data and analytics company. According to GlobalData’s Sales and Forecast database, brensocatib’s sales are anticipated to reach $1.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 7, 2023
Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%
pharmaphorum
NOVEMBER 10, 2022
With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. We are still in a pandemic, but the World Cancer Series congress itself would not have been possible without pharmaceutical companies investing heavily in research on SARS-CoV-2. Pharma needs to continue to invest in M&D.
Pharmaceutical Technology
DECEMBER 22, 2022
By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations. Will the joint procedure drive positive change?
Expert insights. Personalized for you.
105 
Let's personalize your content